Dynastat

Country: Kesatuan Eropah

Bahasa: Inggeris

Sumber: EMA (European Medicines Agency)

Beli sekarang

Risalah maklumat Risalah maklumat (PIL)
05-03-2024
Ciri produk Ciri produk (SPC)
05-03-2024
Laporan Penilaian Awam Laporan Penilaian Awam (PAR)
13-07-2020

Bahan aktif:

parecoxib sodium

Boleh didapati daripada:

Pfizer Europe MA EEIG

Kod ATC:

M01AH04

INN (Nama Antarabangsa):

parecoxib

Kumpulan terapeutik:

Coxibs, Antiinflammatory and antirheumatic products

Kawasan terapeutik:

Pain, Postoperative

Tanda-tanda terapeutik:

For the short-term treatment of postoperative pain in adults.,

Ringkasan produk:

Revision: 32

Status kebenaran:

Authorised

Tarikh kebenaran:

2002-03-22

Risalah maklumat

                                52
B. PACKAGE LEAFLET
53
PACKAGE LEAFLET: INFORMATION FOR THE USER
DYNASTAT 40 MG POWDER FOR SOLUTION FOR INJECTION
parecoxib
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have further questions, ask your doctor or nurse.
-
If you get any side effects, talk to your doctor or nurse. This
includes any possible side effects
not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Dynastat is and what it is used for
2.
What you need to know before you use Dynastat
3.
How to use Dynastat
4.
Possible side effects
5.
How to store Dynastat
6.
Contents of the pack and other information
1.
WHAT DYNASTAT IS AND WHAT IT IS USED FOR
Dynastat contains the active substance parecoxib.
Dynastat is used for the short-term treatment of pain in adults after
an operation. It is one of a family
of medicines called COX-2 inhibitors (this is short for
_cyclo-oxygenase-2 inhibitors_
). Pain and
swelling are sometimes caused by substances in the body called
_prostaglandins_
. Dynastat works by
lowering the amount of these prostaglandins.
2.
WHAT YOU NEED TO KNOW BEFORE YOU USE DYNASTAT
DO NOT USE DYNASTAT
-
if you are allergic to parecoxib or any of the other ingredients of
this medicine (listed in section 6)
-
if you have had a serious allergic reaction (especially a serious skin
reaction) to any medicines
-
if you have had an allergic reaction to a group of medicines called
“sulfonamides” (e.g. some
antibiotics used to treat infections)
-
if you currently have a gastric or intestinal ulcer or bleeding in the
stomach or gut
-
if you have had an allergic reaction to acetylsalicylic acid (aspirin)
or to other NSAIDs (e.g.
ibuprofen) or to COX-2 inhibitors. Reactions might include wheezing
(bronchospasm), badly
blocked nose, itchy skin, rash or swelling of the face, lips or
tongue, other allergic reactions or
nasal polyps after taking these medicines
-
if you are more than 6 months p
                                
                                Baca dokumen lengkap
                                
                            

Ciri produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Dynastat 40 mg powder for solution for injection
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
_ _
Each vial contains 40 mg parecoxib (as 42.36 mg parecoxib sodium).
After reconstitution, the
concentration of parecoxib is 20 mg/ml. Each 2 ml of reconstituted
powder contains 40 mg of
parecoxib.
Excipient with known effect
This medicinal product contains less than 1 mmol sodium (23 mg) per
dose.
When reconstituted in sodium chloride 9 mg/ml (0.9%) solution,
Dynastat contains approximately
0.44 mmol of sodium per vial.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Powder for solution for injection (powder for injection).
White to off-white powder.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
For the short-term treatment of postoperative pain in adults.
The decision to prescribe a selective cyclooxygenase-2 (COX-2)
inhibitor should be based on an
assessment of the individual patient's overall risks (see sections 4.3
and 4.4).
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
The recommended dose is 40 mg administered intravenously (IV) or
intramuscularly (IM), followed
every 6 to 12 hours by 20 mg or 40 mg as required, not to exceed 80
mg/day.
As the cardiovascular risk of COX-2 specific inhibitors may increase
with dose and duration of
exposure, the shortest duration possible and the lowest effective
daily dose should be used. There is
limited clinical experience with Dynastat treatment beyond three days
(see section 5.1).
Concomitant use with opioid analgesics
_ _
Opioid analgesics can be used concurrently with parecoxib, dosing as
described in the paragraph
above. In all clinical assessments parecoxib was administered at a
fixed time interval whereas the
opioids were administered on as needed basis.
Elderly
No dose adjustment is generally necessary in elderly patients (≥65
years). However, for elderly
patients weighing less than 50 kg, treatment should be initiated with
half the usual recommended dose
                                
                                Baca dokumen lengkap
                                
                            

Dokumen dalam bahasa lain

Risalah maklumat Risalah maklumat Bulgaria 05-03-2024
Ciri produk Ciri produk Bulgaria 05-03-2024
Laporan Penilaian Awam Laporan Penilaian Awam Bulgaria 13-07-2020
Risalah maklumat Risalah maklumat Sepanyol 05-03-2024
Ciri produk Ciri produk Sepanyol 05-03-2024
Laporan Penilaian Awam Laporan Penilaian Awam Sepanyol 13-07-2020
Risalah maklumat Risalah maklumat Czech 05-03-2024
Ciri produk Ciri produk Czech 05-03-2024
Laporan Penilaian Awam Laporan Penilaian Awam Czech 13-07-2020
Risalah maklumat Risalah maklumat Denmark 05-03-2024
Ciri produk Ciri produk Denmark 05-03-2024
Laporan Penilaian Awam Laporan Penilaian Awam Denmark 13-07-2020
Risalah maklumat Risalah maklumat Jerman 05-03-2024
Ciri produk Ciri produk Jerman 05-03-2024
Laporan Penilaian Awam Laporan Penilaian Awam Jerman 13-07-2020
Risalah maklumat Risalah maklumat Estonia 05-03-2024
Ciri produk Ciri produk Estonia 05-03-2024
Laporan Penilaian Awam Laporan Penilaian Awam Estonia 13-07-2020
Risalah maklumat Risalah maklumat Greek 05-03-2024
Ciri produk Ciri produk Greek 05-03-2024
Laporan Penilaian Awam Laporan Penilaian Awam Greek 13-07-2020
Risalah maklumat Risalah maklumat Perancis 05-03-2024
Ciri produk Ciri produk Perancis 05-03-2024
Laporan Penilaian Awam Laporan Penilaian Awam Perancis 13-07-2020
Risalah maklumat Risalah maklumat Itali 05-03-2024
Ciri produk Ciri produk Itali 05-03-2024
Laporan Penilaian Awam Laporan Penilaian Awam Itali 13-07-2020
Risalah maklumat Risalah maklumat Latvia 05-03-2024
Ciri produk Ciri produk Latvia 05-03-2024
Laporan Penilaian Awam Laporan Penilaian Awam Latvia 13-07-2020
Risalah maklumat Risalah maklumat Lithuania 05-03-2024
Ciri produk Ciri produk Lithuania 05-03-2024
Laporan Penilaian Awam Laporan Penilaian Awam Lithuania 13-07-2020
Risalah maklumat Risalah maklumat Hungary 05-03-2024
Ciri produk Ciri produk Hungary 05-03-2024
Laporan Penilaian Awam Laporan Penilaian Awam Hungary 13-07-2020
Risalah maklumat Risalah maklumat Malta 05-03-2024
Ciri produk Ciri produk Malta 05-03-2024
Laporan Penilaian Awam Laporan Penilaian Awam Malta 13-07-2020
Risalah maklumat Risalah maklumat Belanda 05-03-2024
Ciri produk Ciri produk Belanda 05-03-2024
Laporan Penilaian Awam Laporan Penilaian Awam Belanda 13-07-2020
Risalah maklumat Risalah maklumat Poland 05-03-2024
Ciri produk Ciri produk Poland 05-03-2024
Laporan Penilaian Awam Laporan Penilaian Awam Poland 13-07-2020
Risalah maklumat Risalah maklumat Portugis 05-03-2024
Ciri produk Ciri produk Portugis 05-03-2024
Laporan Penilaian Awam Laporan Penilaian Awam Portugis 13-07-2020
Risalah maklumat Risalah maklumat Romania 05-03-2024
Ciri produk Ciri produk Romania 05-03-2024
Laporan Penilaian Awam Laporan Penilaian Awam Romania 13-07-2020
Risalah maklumat Risalah maklumat Slovak 05-03-2024
Ciri produk Ciri produk Slovak 05-03-2024
Laporan Penilaian Awam Laporan Penilaian Awam Slovak 13-07-2020
Risalah maklumat Risalah maklumat Slovenia 05-03-2024
Ciri produk Ciri produk Slovenia 05-03-2024
Laporan Penilaian Awam Laporan Penilaian Awam Slovenia 13-07-2020
Risalah maklumat Risalah maklumat Finland 05-03-2024
Ciri produk Ciri produk Finland 05-03-2024
Laporan Penilaian Awam Laporan Penilaian Awam Finland 13-07-2020
Risalah maklumat Risalah maklumat Sweden 05-03-2024
Ciri produk Ciri produk Sweden 05-03-2024
Laporan Penilaian Awam Laporan Penilaian Awam Sweden 13-07-2020
Risalah maklumat Risalah maklumat Norway 05-03-2024
Ciri produk Ciri produk Norway 05-03-2024
Risalah maklumat Risalah maklumat Iceland 05-03-2024
Ciri produk Ciri produk Iceland 05-03-2024
Risalah maklumat Risalah maklumat Croat 05-03-2024
Ciri produk Ciri produk Croat 05-03-2024
Laporan Penilaian Awam Laporan Penilaian Awam Croat 13-07-2020

Cari amaran yang berkaitan dengan produk ini

Lihat sejarah dokumen